Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information (Tables)

v3.4.0.3
Note 3 - Segment Information (Tables)
 9 Months Ended
Mar. 31, 2016
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
March 31,
 
 
Nine Months Ended
March 31,
 
 
 
2016
 
 
2015
 
 
2016
 
 
2015
 
Net sales:
                                
Biotechnology
   $ 81,386     $ 78,521     $ 232,984     $ 229,347  
Clinical Controls
     29,929       20,001       76,013       56,417  
Protein Platforms
     19,693       15,669       55,327       49,061  
Intersegment
     (35
)
     (33
)
     (63
)
     (242
)
Consolidated net sales
     130,973       114,158       364,261       334,583  
                                 
Segment operating income:
                                
Biotechnology
     45,133       44,620       124,436       122,967  
Clinical Controls
     9,454       6,186       21,464       17,422  
Protein Platforms
     1,592       (1,710
)
     1,948       4,461  
Segment operating income
     56,179       49,096       147,848       144,850  
                                 
Costs recognized on sale of acquired inventory
     (1,082
)
     (897
)
     (3,439
)
     (5,252
)
Amortization of acquisition related intangible assets
     (7,276
)
     (6,751
)
     (22,048
)
     (19,337
)
Acquisition related expenses
     (1,313
)
     (335
)
     (2,284
)
     (3,906
)
Stock based compensation
     (2,317
)
     (1,288
)
     (6,676
)
     (4,725
)
Corporate general, selling, and administrative
     (664
)
     (399
)
     (2,820
)
     (2,408
)
Operating income
   $ 43,527     $ 39,426     $ 110,581     $ 109,222